Back

Safety, tolerability, and efficacy of uptitration of guideline-directed medical therapy for acute heart failure stratified by baseline risk

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alex Chang

Kaiser Permanente, San Francisco Medical Centre and Medical Offices, San Francisco (United States of America)

6 More presentations in this session

Presentation thumbnail
Renin-angiotensin-aldosterone system inhibitor discontinuation and its impact on one-year mortality in heart failure patients with acute kidney injury: a propensity matched analysis
Doctor D. Feldman (Newark, US)
Abstract Slides Video
Presentation thumbnail
Deformation Imaging by Strain in Chronic heart failure Over gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 inhibitors (DISCOVER SGLT2i)
Doctor A. Stefanini (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Initial safety of targeted immune activation with the amyloid depleter ALXN2220
Professor T. Damy (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Age-stratified and sex-stratified effect of angiotensin receptor-neprilysin inhibitor in heart failure with reduced ejection fraction-data from PARADE-HF: nationwide medication adherence study
Doctor M. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Representation of frailty in contemporary trials of heart failure medications: a systematic review and dose-response meta-analysis
Doctor D. Rodolico (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Titration of guideline directed medical therapy in a high-risk heart failure patients and impact on heart failure events
thumbnail
Congress Presentation
Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy
thumbnail
Congress Presentation
Relationship between left ventricular reverse remodeling and guideline-directed medical therapy intensity in de novo heart failure with reduced ejection fraction patients: insight from TRANS-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources